| You are here: Home: BCU 9|2003 - Supplement : Case 6: From the practice of Elisa Krill, MD: Select publications
Select publications
Sequencing of endocrine agents in the metastatic setting
Buzdar AU. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist 2003;8(4):335-41. Abstract
Buzdar AU. Endocrine therapy in the treatment of metastatic breast cancer. Semin Oncol 2001;28(3):291-304. Abstract
Carlson RW. Sequencing of endocrine therapies in breast cancer-integration of recent data. Breast Cancer Res Treat 2002;75 (Suppl 1)S27-32;discussion S33-5. Abstract
Carlson RW, Henderson IC. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. Breast Cancer Res Treat 2003;80 (Suppl 1)19-26; discussion 27-8. Abstract
Howell A. Postmenopausal women with advanced breast cancer who progress on fulvestrant or tamoxifen retain sensitivity to further endocrine therapies. Breast Cancer Res Treat 2002;Abstract 251.
Morris C, Wakeling A. Fulvestrant ('Faslodex')-A new treatment option for patients progressing on prior endocrine therapy. Endocr Relat Cancer 2002;9(4):267-76. Abstract
Osborne CK et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 2002;20(16):3386-95. Abstract
Parker LM. Sequencing of hormonal therapy in postmenopausal women with metastatic breast cancer. Clin Ther 2002;24 (Suppl C)43-57. Abstract
Perey L et al. Fulvestrant ('Faslodex') as a hormonal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamoxifen and non-steroidal aromatase inhibitors: An ongoing Phase II SAKK trial. San Antonio Breast Cancer Symposium 2002;Poster 249. No abstract available.
Rose C. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer. Am J Clin Oncol 2003;26(4 Suppl):S9-S16. Abstract
Carcinomatous meningitis
Boogerd W et al. Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology 2000;55(1):117-9. Abstract
Gaur S. Breast cancer relapsing as carcinomatous meningitis. South Med J 2003;96(7):728. Abstract.
Hara H et al. Interventricular methotrexate therapy for carcinomatous meningitis due to breast cancer: A case with leukoencephalopathy. Breast Cancer 2000;7(3):247-51. Abstract
Jaeckle KA et al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 2001;84(2):157-63. Abstract
Kosmas C et al. Isolated leptomeningeal carcinomatosis (carcinomatous meningitis) after taxane-induced major remission in patients with advanced breast cancer. Oncology 2002;63(1):6-15. Abstract
Lauby G. Carcinomatous meningitis in a patient with metastatic breast cancer. Clin Lab Sci 2001;14(3):141-4. Abstract
Orlando L et al. Intrathecal chemotherapy in carcinomatous meningitis from breast cancer. Anticancer Res 2002;22(5):3057-9. Abstract
Robins HI et al. Trastuzumab for breast cancer-related carcinomatous meningitis. Clin Breast Cancer 2002;2(4):316. Abstract.
|
